DE GIGLIO, ANDREA
DE GIGLIO, ANDREA
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Ricercatori a tempo determinato
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib
2024 Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F.
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
2024 Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Giglio A.
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy
2024 De Giglio A.; Di Federico A.; Gariazzo E.; Metro G.
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report
2023 Li B.; Jia Z.; Huang Z.; Xue J.; Wang Y.; Guo C.; Si X.; Chen Z.; Li J.; Chen R.; Bie Z.; De Giglio A.; Christopoulos P.; Liang N.; Li S.
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
2023 Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Prelaj A.; Lopez-Castro R.; Bosch-Barrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar Nana F.; Ponce S.; Albarran-Artahona V.; Dal Maso A.; Spotti M.; Mielgo X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.B.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Mezquita L.; Planchard D.
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients
2023 De Giglio A.; Deiana C.; Di Federico A.
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
2023 Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, Rita; Potena, Luciano
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
2023 Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A.
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond
2023 Mosca M.; Nigro M.C.; Pagani R.; De Giglio A.; Di Federico A.
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
2023 Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M.
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis
2023 Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
2023 Di Federico A.; Ricciotti I.; Favorito V.; Michelina S.V.; Scaparone P.; Metro G.; De Giglio A.; Pecci F.; Lamberti G.; Ambrogio C.; Ricciuti B.
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
2023 De Giglio A.; Ricciuti B.; Metro G.
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
2022 Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G.
Advanced non-small-cell lung cancer: how to manage non-oncogene disease
2022 De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities
2022 De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R.
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
2022 Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Lobefaro R.; Lopez-Castro R.; Bosch-Barrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar-Nana F.; Ponce S.; Dal Maso A.; Spotti M.; Mielgo-Rubio X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Planchard D.; Mezquita L.
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
2022 De Giglio A.; Di Federico A.; Metro G.
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
2022 Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Francesca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib | Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F. | 2024-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) | Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Gi...glio A. | 2024-01-01 | DIAGNOSTICS | - | 1.01 Articolo in rivista | diagnostics-14-00048-v2.pdf |
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy | De Giglio A.; Di Federico A.; Gariazzo E.; Metro G. | 2024-01-01 | MED | - | 1.01 Articolo in rivista | - |
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report | Li B.; Jia Z.; Huang Z.; Xue J.; Wang Y.; Guo C.; Si X.; Chen Z.; Li J.; Chen R.; Bie Z.; De Gigl...io A.; Christopoulos P.; Liang N.; Li S. | 2023-01-01 | TRANSLATIONAL LUNG CANCER RESEARCH | - | 1.01 Articolo in rivista | 80018-PB6-4841-R2.pdf; 2322.zip |
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer | Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Prelaj A.; Lopez-Castro R.; Bosch-Bar...rera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar Nana F.; Ponce S.; Albarran-Artahona V.; Dal Maso A.; Spotti M.; Mielgo X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.B.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Mezquita L.; Planchard D. | 2023-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients | De Giglio A.; Deiana C.; Di Federico A. | 2023-01-01 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | De_Giglio_2023.pdf; 432_2022_4120_MOESM1_ESM.png |
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians | Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, ...Rita; Potena, Luciano | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | Raschi et al., Drug Safety Cardiotoxicity ICI 2023.pdf; 40264_2023_1320_MOESM1_ESM.pdf |
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review | Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A. | 2023-01-01 | LUNG CANCER: TARGETS AND THERAPY | - | 1.01 Articolo in rivista | - |
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond | Mosca M.; Nigro M.C.; Pagani R.; De Giglio A.; Di Federico A. | 2023-01-01 | BIOMOLECULES | - | 1.01 Articolo in rivista | biomolecules-13-01803.pdf |
Peripheral nervous system adverse events associated with immune checkpoint inhibitors | Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lambert...i G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M. | 2023-01-01 | JOURNAL OF NEUROLOGY | - | 1.01 Articolo in rivista | Rossi_JN_2023.pdf |
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis | Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, B...arbara; Ardizzoni, Andrea | 2023-01-01 | JOURNAL OF THE NATIONAL CANCER INSTITUTE | - | 1.01 Articolo in rivista | - |
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer | Di Federico A.; Ricciotti I.; Favorito V.; Michelina S.V.; Scaparone P.; Metro G.; De Giglio A.; ...Pecci F.; Lamberti G.; Ambrogio C.; Ricciuti B. | 2023-01-01 | CURRENT ONCOLOGY REPORTS | - | 1.01 Articolo in rivista | - |
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks | De Giglio A.; Ricciuti B.; Metro G. | 2023-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | dic.2022-11-4.pdf |
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease | Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.;... Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | - |
Advanced non-small-cell lung cancer: how to manage non-oncogene disease | De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | dic.2022-2-4.pdf |
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials | Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G. | 2022-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities | De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R. | 2022-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations | Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Lobefaro R.; Lopez-Castro R.; Bosch-B...arrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar-Nana F.; Ponce S.; Dal Maso A.; Spotti M.; Mielgo-Rubio X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Planchard D.; Mezquita L. | 2022-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer | De Giglio A.; Di Federico A.; Metro G. | 2022-01-01 | TRANSLATIONAL LUNG CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes | Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Franc...esca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-03472-v2.pdf; cancers-14-03472-s001.zip |